Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Diabetes Care|February 16, 2013
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled studyDavid Polidori, Sue Sha, Sunder Mudaliar, et al.
Plos One|August 29, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetesSue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
Clinical and Translational Science|May 8, 2023
A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate modelSongmao Zheng, David Polidori, Yuanping Wang, et al.
Obesity Surgery|June 29, 2014
Effects of meal size on the release of GLP-1 and PYY after Roux-en-Y gastric bypass surgery in obese subjects with or without type 2 diabetesWen Yan, David Polidori, Lynn Yieh, et al.
Diabetologia|March 28, 2015
Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetesWilliam T Cefalu, Kaj Stenlöf, Lawrence A Leiter, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventionsRaul C Camacho, David Polidori, Tao Chen, et al.
Plos One|February 23, 2012
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsYin Liang, Kenji Arakawa, Kiichiro Ueta, et al.
Diabetes, Obesity & Metabolism|November 18, 2018
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesKenneth Cusi, Fernando Bril, Diana Barb, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 21, 2018
Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in RodentsFuyong Du, Simon A Hinke, Cassandre Cavanaugh, et al.
Annals of the New York Academy of Sciences|August 26, 2015
Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitusNorm Rosenthal, Gary Meininger, Kirk Ways, et al.
Pageof 5